Treatment completion rates of olanzapine and risperidone in long acting injectable formulations for the treatment of schizophrenia: A comparison of single arm open-label studies

被引：0
|
作者：
Ascher-Svanum, H. [1 ]
Montgomery, W. [1 ]
Brnabic, A. [2 ]
Lawson, A. [1 ]
Tomori, O. [1 ]
Coleman, K. [3 ]
Lynch, L. [3 ]
Chen, P. [4 ]
Andersen, S. W. [1 ]
McDonnell, D. P. [1 ]
机构：
[1] Eli Lilly & Co, Lilly Res Labs, Indianapolis, IN 46285 USA
[2] Eli Lilly & Co, N Ryde, NSW, Australia
[3] Hlth Technol Analysts, Balmain, NSW, Australia
[4] Eli Lilly & Co, Singapore, Singapore
来源：
INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY | 2008年 / 11卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：161 / 162
页数：2
相关论文
共 50 条
  • [1] Treatment-completion rates with olanzapine long-acting injection versus risperidone long-acting injection in a 12-month, open-label treatment of schizophrenia: indirect, exploratory comparisons
    Ascher-Svanum, Haya
    Montgomery, William S.
    McDonnell, David P.
    Coleman, Kristina A.
    Feldman, Peter D.
    INTERNATIONAL JOURNAL OF GENERAL MEDICINE, 2012, 5 : 391 - 398
  • [2] An open-label randomized comparison of olanzapine versus risperidone in the treatment of childhood-onset schizophrenia
    Mozes, Tamar
    Ebert, Tanya
    Michal, Sabbagh-Etun
    Spivak, Baruch
    Weizman, Abraham
    JOURNAL OF CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY, 2006, 16 (04) : 393 - 403
  • [3] An open-label trial of risperidone long-acting injectable in the treatment of subject with recent onset psychosis
    Emsley, R.
    Schreiner, A.
    Koen, L.
    Oosthuizen, P.
    Niehaus, D.
    Rabinowitz, J.
    EARLY INTERVENTION IN PSYCHIATRY, 2008, 2 : A100 - A100
  • [4] Long-acting injectable risperidone v. olanzapine tablets for schizophrenia or schizoaffective disorder - Randomised, controlled, open-label study
    Keks, Nicholas A.
    Ingham, Michael
    Khan, Akbar
    Karcher, Keith
    BRITISH JOURNAL OF PSYCHIATRY, 2007, 191 : 131 - 139
  • [5] Long-acting injectable risperidone for the treatment of schizophrenia
    Moeller, Hans-Juergen
    DRUGS, 2007, 67 (11) : 1541 - 1566
  • [6] Comparison of treatment completion rates for olanzapine pamoate and risperidone microspheres
    Akhras, K. S.
    Singh, J.
    Gopal, S.
    Schadrack, J.
    Palumbo, J. M.
    INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2009, 63 (06) : 962 - 963
  • [7] Quality of life in the treatment of schizophrenia - A randomized, open-label comparison trial of amisulpride, olanzapine, quetiapine, risperidone and zotepine
    Lambert, M
    Moritz, S
    Karow, A
    Krausz, M
    Naber, D
    SCHIZOPHRENIA RESEARCH, 2002, 53 (03) : 176 - 176
  • [8] Treatment of schizophrenia with long-acting injectable risperidone: A 12-month open-label trial of the first long-acting second-generation antipsychotic
    Fleischhacker, WW
    Eerdekens, M
    Karcher, K
    Remington, G
    Llorca, PM
    Chrzanowski, W
    Martin, S
    Gefvert, O
    JOURNAL OF CLINICAL PSYCHIATRY, 2003, 64 (10) : 1250 - 1257
  • [9] A prospective, open-label study to evaluate symptomatic remission in schizophrenia with risperidone long-acting injectable in Korea
    Lee, Nam Young
    Kim, Se Hyun
    Cho, Seong Jin
    Chung, Young-Cho
    Jung, In Kwa
    Kim, Chang Yoon
    Kim, Duk Ho
    Lee, Dong Geun
    Lee, Yo Han
    Lim, Weon Jeong
    Na, Young Suk
    Shin, Sang Eun
    Woo, Jong-Min
    Yoon, Jin Sang
    Yoon, Bo-Hyun
    Ahn, Yong Min
    Kim, Yong Sik
    INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 2014, 29 (05) : 279 - 287
  • [10] Long-acting injectable risperidone in treatment refractory patients: A 14-week open-label pilot study
    Procyshyn, Ric M.
    Barr, Alasdair M.
    Flynn, Sean
    Schenk, Chris
    Ganesan, Soma
    Honer, William G.
    SCHIZOPHRENIA RESEARCH, 2010, 123 (2-3) : 273 - 275
12345